Showing results (211-220 of 253) with videos related to

Sort By:
Pageof 26
The Lancet. HIV|December 9, 2021
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation studyAdrie Bekker, Edmund V Capparelli, Avy Violari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2021
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in ChildrenKendra K Radtke, Anneke C Hesseling, J L Winckler, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2018
Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte StagesDina Coertzen, Janette Reader, Mariëtte van der Watt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2021
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic StudyPaolo Denti, Roeland E Wasmann, Annelies van Rie, et al.
AIDS (London, England)|May 11, 2021
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimenClaire M Keene, Rulan Griesel, Ying Zhao, et al.
The Journal of Antimicrobial Chemotherapy|September 16, 2021
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trialAnthony J Garcia-Prats, Elin M Svensson, Jana Winckler, et al.
The Lancet. HIV|May 11, 2025
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trialEthel D Weld, Trevor Beattie, Jayajothi Moodley, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years OldAwewura Kwara, Hongmei Yang, Sampson Antwi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO TrialIvana Beesham, Leila E Mansoor, Dvora L Joseph Davey, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
Pageof 26